Home Cart Sign in  
Chemical Structure| 596-09-8 Chemical Structure| 596-09-8
Chemical Structure| 596-09-8

Fluorescein Diacetate

CAS No.: 596-09-8

Fluorescein diacetate is a cell-permeant esterase substrate that can serve as a viability probe that measures both enzymatic activity, which is require to activate its fluorescence, and cell-membrane integrity, which is required for intracellular retention of their fluorescent product.

Synonyms: 3,6-Diacetoxyfluoran; Di-O-acetylfluorescein; NSC 667259

4.5 *For Research Use Only !

Cat. No.: A247101 Purity: 98%

Change View

Size Price

US Stock

Global Stock

In Stock
1g łÇ§¶ÊÊ Inquiry Inquiry
5g ł§î¶ÊÊ Inquiry Inquiry
25g łÇÇó¶ÊÊ Inquiry Inquiry
100g ł§óî¶ÊÊ Inquiry Inquiry

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1g

    łÇ§¶ÊÊ

  • 5g

    ł§î¶ÊÊ

  • 25g

    łÇÇó¶ÊÊ

  • 100g

    ł§óî¶ÊÊ

In Stock

- +

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support Online Technical Q&A
Product Citations

Alternative Products

Product Details of Fluorescein Diacetate

CAS No. :596-09-8
Formula : C24H16O7
M.W : 416.37
SMILES Code : O=C1OC2(C3=C(OC4=C2C=CC(OC(C)=O)=C4)C=C(OC(C)=O)C=C3)C5=C1C=CC=C5
Synonyms :
3,6-Diacetoxyfluoran; Di-O-acetylfluorescein; NSC 667259
MDL No. :MFCD00005062
InChI Key :CHADEQDQBURGHL-UHFFFAOYSA-N
Pubchem ID :65047

Safety of Fluorescein Diacetate

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Fluorescein Diacetate

DNA

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00242580 Macular Degeneration ... More >> Choroidal Neovascularization Less << Phase 3 Completed - United States, Texas ... More >> Novartis Investigational Site Austin, Texas, United States, 78793 Less <<
NCT02294656 CYSTOID MACULAR EDEMA Phase 1 Completed - United States, Pennsylvania ... More >> Soll Eye Philadelphia, Pennsylvania, United States, 19116 Less <<
NCT00815360 - Completed - -
NCT00815360 Diabetic Macular Edema Phase 2 Completed - United States, Florida ... More >> Retina Associates of Florida Tampa, Florida, United States, 33609 Less <<
NCT00105404 Diabetic Retinopathy ... More >> Diabetic Macular Edema DME Less << Phase 3 Completed - United States, Maryland ... More >> National Eye Institute (NEI) Bethesda, Maryland, United States, 20892 Less <<
NCT00100009 Macular Degeneration Phase 3 Completed - -
NCT00685100 Neovascular Age Related Macula... More >>r Degeneration Less << Phase 3 Completed - -
NCT00242580 - Completed - -
NCT00231023 Diabetic Retinopathy Phase 2 Completed - United States, Maryland ... More >> National Eye Institute (NEI) Bethesda, Maryland, United States, 20892 Less <<
NCT00532142 Central Retinal Vein Occlusion Phase 2 Phase 3 Completed - Austria ... More >> Rudolf foundation Clinic Vienna, Austria, A1030 Less <<
NCT00411333 Diabetic Retinopathy Early Phase 1 Completed - United States, Ohio ... More >> Cole Eye Institute Cleveland, Ohio, United States, 44195 Less <<
NCT00106132 Retinal Vein Occlusion ... More >> Macular Edema, Cystoid Macular Edema Less << Phase 3 Completed - United States, Maryland ... More >> National Eye Institute (NEI) Bethesda, Maryland, United States, 20892 Less <<
NCT01918501 Multiple Sclerosis Not Applicable Unknown July 2015 Israel ... More >> ZIV Medical Center Recruiting Safed, Israel, 13100 Contact: Ayelet Omer-Armon, PHD    972-4-6828146    ayelet.o@ziv.health.gov.il    Sub-Investigator: Ayelet Omer-Armon, PHD          Sub-Investigator: Saad Abu Saleh, MD          Sub-Investigator: Adi Nov-Sharabi Less <<
NCT03303963 - Recruiting May 31, 2021 Belgium ... More >> Institute of Tropical Medecine Active, not recruiting Antwerp, Belgium Benin Centre National Hospitalier Universitaire de Pneumo-Phtisiologie de Cotonou Recruiting Cotonou, Atlantique/Littoral, Benin, 01BP321 Contact: Dissou AFFOLABI, MD PhD Prof    66614862 ext 00229    affolabi_dissou@yahoo.fr    Contact: Faridath MASSOU, PharmD    67244944 ext 00229    abenimas@gmail.com    Cameroon The Tuberculosis Reference Laboratory Bamenda Recruiting Bamenda, Cameroon Contact: Melissa SANDER, MSc, PhD    694721484 ext 00237    melissa.sander@gmail.com    Congo, The Democratic Republic of the Institut National de Recherche Biomédicale (INRB) Recruiting Kinshasa, Congo, The Democratic Republic of the Contact: Michel KASWA, MD MSc MPH    999928694 ext 00243    meckkay2002@yahoo.fr    Ethiopia Jimma University Not yet recruiting Jīma, Ethiopia Contact: Gemeda Ayana ABEBE, MSc PhD Associate Prof    911991285 ext 00251    Gemeda.abebe@ju.edu.et    Guinea Service de Pneumophtisiologie, Hôpital Ignace Deen, Conakry Recruiting Conakry, Guinea Contact: Oumou Younoussa BAH-SOW, MD, Prof    664962434 ext 00224    oumou45@yahoo.fr    Mali Université des Sciences, des Techniques et des Technologies de Bamako, SEREFO Recruiting Bamako, Mali Contact: Bassirou DIARRA, MD MSc PhD Student    66807491 ext 00223    bdiarra@icermali.org    Nigeria Damien Fundation Not yet recruiting Ibadan, Nigeria Contact: Othman EL TAYEB, BSc MSc    8023683356 ext 00234    osman.eltayeb@dfbnigeria.org    Rwanda Rwanda Biomedical Center (RBC) Recruiting Kigali, Rwanda Contact: Jean-Claude SEMUTO NGABONZIZA, MSc PhD student    788740490 ext 00250    cldsemuto@gmail.com    Senegal Université Cheick Anta Diop (UCAD) Not yet recruiting Dakar, Senegal Contact: Aïssatou GAYE-DIALLO, PharmD Prof    338225919 ext 00221    ayougayediallo@gmail.com Less <<
NCT00305630 Choroidal Neovascularization ... More >> Age-Related Macular Degeneration Less << Phase 2 Phase 3 Completed - United States, Maryland ... More >> Johns Hopkins Univeristy School of Medicine Baltimore, Maryland, United States, 21287 United States, Oregon Oregon Health Science Univeristy Portland, Oregon, United States, 97239 Less <<
NCT00071227 Macular Degeneration ... More >> Retinal Vein Occlusion Less << Phase 1 Completed - United States, Maryland ... More >> National Institutes of Health Clinical Center, 9000 Rockville Pike Bethesda, Maryland, United States, 20892 Less <<
NCT00407706 - Unknown - Israel ... More >> Surgery Department Recruiting Safed, Israel, 13110 Contact: Amram Hadari, MD    + 972 4 6828923       Contact: Tali Keren, MA    + 972 4 682 8828       Principal Investigator: Amram Hadari, MD          Sub-Investigator: Tali Keren, MA Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.40mL

0.48mL

0.24mL

12.01mL

2.40mL

1.20mL

24.02mL

4.80mL

2.40mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories